This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Oncology, Other  • Randomized Controlled Trial  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

A Case for More Innovation

Eric X. Chen, MD, PhD; Ian F. Tannock, MD, PhD

JAMA. 2004;292:2150-2151.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The development of new anticancer agents follows a well-established paradigm that progresses sequentially from phase 1 through phase 3 clinical trials. Phase 1 clinical trials are first in human studies of investigational agents and enroll patients with advanced or refractory disease for whom no standard options exist. The starting dose is usually about one tenth of the lethal dose in animals that have been used for preclinical studies of toxicity. Cohorts of 3 to 6 patients are treated at each dose level, and the dose escalation in most studies involves higher escalation steps with decreasing relative increments.¹ Dose escalation within the same patient is not permitted in most studies because of the desire to evaluate patients for cumulative or delayed toxicity at lower doses. The primary objectives of phase 1 studies are to evaluate the safety and tolerability of new . . . [Full Text of this Article]

Author Affiliation: Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Thomas G. Roberts, Jr, Bernardo H. Goulart, Lee Squitieri, Sarah C. Stallings, Elkan F. Halpern, Bruce A. Chabner, G. Scott Gazelle, Stan N. Finkelstein, and Jeffrey W. Clark
JAMA. 2004;292(17):2130-2140.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.
Dresser
J Law Med Ethics 2009;37:38-50.
 

Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
Chan et al.
JCO 2008;26:1511-1518.
ABSTRACT | FULL TEXT  

Practicalities of drugging the phosphatidylinositol-3-kinase/akt cell survival signaling pathway.
Powis et al.
Clin. Cancer Res. 2006;12:2964-2966.
FULL TEXT  

Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment
Epstein
Clin. Cancer Res. 2005;11:5337-5341.
ABSTRACT | FULL TEXT  

Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Horstmann et al.
NEJM 2005;352:895-904.
ABSTRACT | FULL TEXT